spike protein News
-
Mutations in the SARS-CoV-2 spike protein gene
Immundiagnostik's respiratroy PCR assays MutaPLEX® Coronavirus (KG1926), MutaPLEX® RespiraScreen 1 (KG1927), MutaPLEX® RespiraScreen 2 DIFF (KG1928) and MutaPLEX® Coronavirus 4G (KG1936) were screened for the spike protein mutations in the following viral variants: [Omicron] (BA.1, BA.2, BA.4, BA.5) [Omicron] (BA.3, BA.2 + L452X) [Alpha], [Beta], [Gamma], [Delta] (all AY ...
-
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
Bebtelovimab (LY-CoV1404) neutralizes Omicron, including the subvariant BA.2, as demonstrated by pseudovirus and/or authentic virus data Previously reported data show that bebtelovimab has broad and potent neutralization of all other known circulating SARS-CoV-2 variants of concern Bebtelovimab binds to a rarely mutated region of the SARS-CoV-2 spike protein, suggesting the potential to ...
-
SpyBiotech featured in The Guardian Value of Vaccines supplement
SpyBiotech has today been featured in The Guardian’s Value of Vaccines supplement, discussing the technological solutions we have developed to accelerate vaccine generation for COVID-19 variants and potentially a range of other diseases for which there are no approved treatments. "The COVID-19 vaccine uses SpyBiotech's unique protein "superglue" technology to display the SARS ...
-
NEOVII Partners with Tel Aviv University to Develop Novel COVID-19 Vaccine
Ramot, Tel Aviv University’s technology transfer company, and Neovii, a Swiss-based biopharmaceutical company and a member of Israel-based Neopharm Group, announced today that they have signed a research and license agreement to develop a novel and potentially life-saving COVID-19 vaccine. Neovii will work in close collaboration with a team of scientists led by Prof. Jonathan Gershoni of ...
-
SARS-CoV-2 Glycosylation Profiling Service Now Available at CD BioGlyco
CD BioGlyco, a biotechnology company that offers a full range of glycobiology-related products, analysis, custom synthesis, and design to help advance glycobiology research, now provides customers with comprehensive and accurate viral glycomics information to speed up the development of vaccines and other therapeutic agents during this COVID-19 pandemic. The US FDA has approved Pfizer and ...
By CD BioGlyco.
-
Missing link in coronavirus jump from bats to humans could be pangolins, not snakes
As scientists scramble to learn more about the SARS-CoV-2 coronavirus, two recent studies of the virus’ genome reached controversial conclusions: namely, that snakes are intermediate hosts of the new virus, and that a key coronavirus protein shares “uncanny similarities” with an HIV-1 protein. Now, a study in ACS’ Journal of Proteome Research refutes both ideas and ...
-
Next-generation COVID-19 vaccines – looking beyond spike protein and SARS-CoV-1 variants
The accelerated development of vaccines against COVID-19 and their deployment in mass vaccination programmes has been a major public health achievement. The landscape of vaccine development has undergone rapid change in the global response to the pandemic, with the utilization of novel platforms to create new vaccines at an unprecedented speed. Despite the success of current vaccines in ...
-
Covid-19 vaccine candidates using SpyCatcher/SpyTag to display Spike protein on computationally designed particles and Bacteriophage VLPs
recent papers with really interesting results! Click here to read the full paper on computationally designed VLPs. Results: RBD can be efficiently displayed on the mi3 VLP via SpyTag/SpyCatcher RBD-SpyVLP is reactive to monoclonal antibodies isolated from recovered patients RBD-SpyVLP induces a strong ACE2-blocking and neutralising antibody response in mouse models RBD-SpyVLP is highly ...
-
New Vitassay qPCR kit for SARS-CoV-2 UK Variant detection
The new Vitassay Real Time PCR allows the qualitative detection of SARS-CoV-2 and the HV 69/70 deletion of the S gene for SARS-CoV-2 in respiratory samples. Several SARS-CoV-2 variants of concern (VOC) have emerged in the past months and monitoring them in all countries is key. The United Kingdom (UK) has detected a new variant of SARS-CoV-2 from samples initially taken in Kent on September 20th ...
-
Atriva Therapeutics announces efficacy of its lead compound zapnometinib against Omicron
Strong preclinical evidence of universal efficacy of zapnometinib against coronavirus variants of concernProf. Planz will continue to serve Atriva as Chairman of the Scientific Advisory Board The findings underscore the importance of new therapeutic approaches such as zapnometinib, which can maintain potent efficacy against all coronavirus strains, including Omicron Atriva Therapeutics ...
-
Medigen and BlueWillow Biologics Partner to Develop Intranasal Vaccine for SARS-CoV-2
Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO), a biopharmaceutical company focusing on the development and production of vaccines and biologics, and BlueWillow Biologics, Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines through its patented NanoVax™ adjuvant, today announced a partnership to develop S-2P-NE-01, a nasal vaccine for ...
-
LenioBio awarded prestigious Eurostars grant
DUSSELDORF, Germany, May 09 2022- LenioBio GmbH announced today that the company has been awarded a 2.75M Euro Eurostars grant to lead a consortiu m comprising one academic and two industrial partners spanning three European countries. Under the project name HiT-GlyP, the consortium comprising LenioBio (Germany), Wageningen University (The Netherlands) and developer of cell-free ...
-
Studies using SpyBiotech’s vaccine technology shows potential against Covid-19 and other Coronaviruses
A research paper demonstrating the potential of SpyBiotech’s SpyCatcher/SpyTag vaccine platform has been published in Science Advances. A Covid-19 vaccine being developed with SpyBiotech’s technology elicited a strong immune response in non-human primates, showing titres of neutralising antibodies (>104) that were above the range of protection provided by other licensed vaccines ...
-
SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19
SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19 Oxford, UK, September 8: SpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases, today announces that its partner the Serum Institute of India (SIIPL) has dosed the first ...
-
ARTES joins global combat against Corona
ARTES Biotechnology, the German-based biotech company specializing in process development for recombinant vaccines, entered development of SARS-CoV-2 vaccine candidates based on its virus-like particle (VLP) based platform technologies METAVAX® and SplitCore. METAVAX® is the company´s platform for the development of vaccines built on enveloped virus-like particle nanostructures ...
-
AIVITA Biomedical Announces Publication of Phase 1 and Phase 2 Trial Results of its COVID-19 Vaccine Candidate
IRVINE, Calif. – AUG. 29, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced the publication of safety and efficacy results from Phase 1 and Phase 2 clinical trials investigating its anti-SARS-CoV-2 vaccine candidate AV-COVID-19 that is made at point-of-care by third-party personnel. The results were published in the article ...
-
Kephera Diagnostics launches CLIA test for quantitative antibody response to COVID-19 vaccination
Kephera Diagnostics announced today the launch of a quantitative test to measure the level of antibodies elicited by vaccination against COVID-19, as well as by COVID-19 infection. The test will be available as a service through Kephera’s CLIA-certified laboratory. Kephera’s COVI-QUANT™ test measures the level of IgG antibodies to the spike protein, a viral component which is ...
-
How to freeze-dry a potential COVID-19 vaccine
Things that are freeze-dried: Astronaut food. Emergency rations. And, just maybe, some future COVID-19 vaccines. Freeze-drying is a method for removing water from a product. First, you freeze the item you’re trying to dehydrate, causing any water in it to become ice. Then, you remove the ice through a process called sublimation, in which ice turns directly into vapor under low pressure. In ...
-
Immune Biosolutions reports that its lead immunotherapy product IBIO123 neutralizes 100% of the SARS-CoV-2 variants of concern (VOCs), including Omicron
Immune Biosolutions Inc., a clinical-stage company, is pleased to announce that its leading biological drug candidate maintains a potent activity in neutralization assays. Recent results have confirmed that this drug, IBIO123, is capable of neutralizing SARS-CoV-2 (COVID-19) and all its current variants of concern (VOCs) that have emerged throughout the pandemic, including the latest Omicron ...
-
Alfa Chemistry-A New Supplier of Vaccine Excipients, Nucleic Acid Delivery Excipients and SARS-CoV-2 Detection Raw Materials
Alfa Chemistry, known as a chemical supplier for various high-quality chemicals and materials for both academia and the industry, has recently extended its offering scope to vaccine related products, including but not limited to: vaccine excipients, nucleic acid delivery excipients, cell culture media and pharmaceutical packaging. “Always bearing in mind that what customers truly need is the top ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you